Yates, Kathleen B. https://orcid.org/0000-0002-7383-5573
Tonnerre, Pierre https://orcid.org/0000-0002-1719-9736
Martin, Genevieve E. https://orcid.org/0000-0001-5142-7440
Gerdemann, Ulrike
Al Abosy, Rose https://orcid.org/0000-0001-5400-1306
Comstock, Dawn E. https://orcid.org/0000-0002-3718-8372
Weiss, Sarah A. https://orcid.org/0000-0002-4155-0346
Wolski, David
Tully, Damien C. https://orcid.org/0000-0002-7620-9340
Chung, Raymond T.
Allen, Todd M. https://orcid.org/0000-0002-6609-1318
Kim, Arthur Y.
Fidler, Sarah
Fox, Julie
Frater, John https://orcid.org/0000-0001-7163-7277
Lauer, Georg M. https://orcid.org/0000-0002-9792-4271
Haining, W. Nicholas https://orcid.org/0000-0001-7871-3762
Sen, Debattama R. https://orcid.org/0000-0002-0947-8284
Funding for this research was provided by:
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (U19 AI086230, U19 AI086230, R01 AI136715)
Parker Institute for Cancer Immunotherapy
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32 GM007753)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (T32 CA207021)
MGH Research Scholars Program
Article History
Received: 19 May 2020
Accepted: 17 June 2021
First Online: 26 July 2021
Competing interests
: AbbVie sponsored the clinical trial () and gave input to the trial design as well as the clinical and biological sample collection schedule. W.N.H. is an employee of Merck and Company and holds equity in Tango Therapeutics and Arsenal Biosciences. The other authors declare no competing interests.